Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
August 2, 2004
- 1st Qtr Business Results
August 2, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
August 2, 2004
- OTC NEWS IN BRIEF
August 2, 2004
- Ban Lifted on Sale of 371 OTC Drugs by General Retailers
August 2, 2004
- SSP to Concentrate on Self-medication
August 2, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 2, 2004
- BULLETIN
August 2, 2004
- REGULATORY NEWS IN BRIEF
August 2, 2004
- METI to Develop Healthcare Service Industry
August 2, 2004
- Standing at a Critical Crossroads: Mr Shimada of Nippon Kayaku
August 2, 2004
- BUSINESS NEWS IN BRIEF
August 2, 2004
- JPMA to Provide Technology, Assistance in Asia in FY2004
August 2, 2004
- Therapeutic Category of 380 Generics Clarified
August 2, 2004
- GE Makers to Distinguish Themselves from Competitors
August 2, 2004
- Meet the Leaders (35)
August 2, 2004
- WORLD NEWS IN BRIEF
July 26, 2004
- PRESS SEMINAR
July 26, 2004
- 2 WG to Discuss Problems with Drug Distribution: Ryukaikon
July 26, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 26, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…